海外の治験の状況「1」での検索結果
148件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- This is a randomized, open-label, multi-center, global, Phase III study to assess the effectiveness and safety of two Immune Therapy drugs, durvalumab given by itself or with tremelimumab versus sorafenib, the standard first line treatment, to treat patients with no prior systemic therapy for liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable).
- unresectable hepatocellular carcinoma (HCC) MedDRA version: 20.0 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Brazil, Canada, China, France, Germany, Hong Kong, India, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Thailand, Ukraine, United States, Vietnam
- 2017-09-06
Authorised
- Study to Evaluate the Long-term Safety and Efficacy of Patisiran (ALN-TTR02) in Patients with Familial Amyloidotic Polyneuropathy (FAP)
- Transthyretin mediated amyloidosis (ATTR) MedDRA version: 17.1 Level: PT Classification code 10007509 Term: Cardiac amyloidosis System Organ Class: 10007541 - Cardiac disorders MedDRA version: 17.1 Level: PT Classification code 10019889 Term: Hereditary neuropathic amyloidosis System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Brazil, Bulgaria, Canada, France, Germany, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
- 2015-03-03
Authorised
- Safety and efficacy study of roxadustat to treat anemia in patients with lower risk Myelodysplastic Syndrome (MDS), who require 1 to 4 packs of Red Blood Cells through transfusion every 8-weeks.
- Anemia due to Myelodysplastic Syndrome (MDS) in International Prognostic Scoring System – Revised Very Low, Low, or Intermediate Risk with 1 to 4 packed red blood cell units per 8-week period) ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Belgium, Brazil, Germany, Israel, Italy, Korea, Republic of, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom, United States
- 2017-08-18
Authorised
- A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
- Dilated Cardiomyopathy (DCM) with Lamin A/C protein (LMNA) Mutation MedDRA version: 20.0 Level: LLT Classification code 10056419 Term: Dilated cardiomyopathy System Organ Class: 100000004849 ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Argentina, Belgium, Canada, Denmark, France, Germany, Italy, Mexico, Netherlands, Norway, Spain, United Kingdom, United States
- 2018-05-17
Authorised
- A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Subjects Aged 1 to 11 Years
- Symptomatic nonerosive GERD in paediatric subjects aged 1 to 11 years MedDRA version: 18.1 Level: LLT Classification code 10066874 Term: Gastroesophageal reflux disease System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Belgium, Brazil, Israel, Italy, Mexico, Poland, Portugal, United States
- 2015-10-23
Authorised
- Research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetes
- Diabetes Mellitus, Type 1 MedDRA version: 20.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Argentina, Australia, Austria, Brazil, Canada, Denmark, European Union, Greece, Ireland, Israel, Russian Federation, Serbia, Spain, United Kingdom
- 2017-07-19
Authorised
- Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared with Once-Daily Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus on Oral Agents
- Type II diabetes MedDRA version: 14.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Brazil, Indonesia, Spain, United States
- 2012-03-30
Authorised
- A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin.
- Type 1 Diabetes MedDRA version: 20.0 Level: LLT Classification code 10020639 Term: Hyperglycemia System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Argentina, Australia, Austria, Brazil, Germany, Greece, India, Italy, Japan, Mexico, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United States
- 2017-04-03
Authorised
- A study to evaluate the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected patients that have not been treated yet.
- Human Immunodeficiency Virus-1 infection MedDRA version: 20.1 Level: LLT Classification code 10068341 Term: HIV-1 infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Romania, Russian Federation, South Africa, Spain, Taiwan, Ukraine, United Kingdom, United States
- 2016-05-20
Authorised
- A study to evaluate the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV- 1-infected patients that have not been treated yet.
- Human Immunodeficiency Virus-1 infection MedDRA version: 20.1 Level: LLT Classification code 10068341 Term: HIV-1 infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Argentina, Australia, Belgium, Canada, France, Germany, Italy, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, South Africa, Spain, Switzerland, Taiwan, Ukraine, United Kingdom, United States
- 2016-05-25
